LONDON, UK / ACCESSWIRE / July 13, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(“Hemogenyx Pharmaceuticals” or the “Company”), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 6,200,626 ordinary shares of 1p each in the capital of the Company (“Share Options”) to certain PDMRs and a member of the Scientific Advisory Board of the Company.
The details of the Share Options granted are set out below:
|
Name |
Position |
Number of Share Options Granted |
Exercise Price (pence) |
Vesting Date |
Expiry Date |
|
Peter Redmond |
Non-Executive Director |
2,200,000 |
7 |
Vesting in quarterly tranches over the 12 months from 13 July 2020 |
12 July 2025 |
|
Andrew Wright |
Financial Controller (PDMR) |
2,200,000 |
7 |
12 July 2025 |
|
|
Dr Alexander Tarakhovsky |
Scientific Adviser |
1,800,626 |
3.5 |
Immediate |
3 October 2022 |
Following the grant of the Share Options, in aggregate there will be 36,753,702 ordinary shares of 1p each of the Company under option to directors, employees and members of the Scientific Advisory Board of the Company, representing 8.48% of the issued ordinary share capital of the Company.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Soltan Tagiev |
|
|
Peterhouse Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
|
US Media enquiries |
Tel: +1 (323) 646-3249 |
|
Lowell Goodman |
Notification and public disclosure of transactions by persons discharging managerial responsibilities (“PDMR”) and persons closely associated with them (“PCA”):
|
1. |
Details of PDMR/person closely associated with them |
|||||
|
a) |
Name |
1. Peter Redmond 2. Andrew Wright |
||||
|
b) |
Position/status |
1. Non-Executive Director 2. Financial Controller (PDMR, non-board) |
||||
|
c) |
Initial notification/ |
Initial notification |
||||
|
2. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument |
Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc |
||||
|
b) |
Nature of the transaction |
Grant of options |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information – Aggregated volume – Price |
|
||||
|
e) |
Date of the transaction |
13/07/2020 |
||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/597270/Hemogenyx-Pharmaceuticals-PLC-Announces-Grant-of-Options
Los Angeles, California--(Newsfile Corp. - February 4, 2026) - This World Cancer Day, the St.…
Strategic elevation signals bold expansion as Doceree redefines healthcare marketing with AI-powered precision and purposeSHORT…
Next-generation EMR platform recognized for helping specialty practices deliver efficient, personalized patient careSAN FRANCISCO, Feb.…
Agentic AI integrates EHR and RTLS data to automate equipment workflows and improve operational efficiency,…
PUNE, India, Feb. 4, 2026 /PRNewswire/ -- For nearly a decade, robotic surgery was sold as progress.…
Ambitious nationwide study will enroll 500 participants to examine genetic, biological, and environmental factors linked…